The porphyrin-based compound binds to cancer cells and causes them to fluoresce under specific frequencies of light.

Biomoda said its US patent 6,838,248 received in 2005 is similar to the Japanese patent application No. 2008-266490, ‘Compositions and Methods for Detecting Pre-Cancerous Conditions In Cell And Tissue Samples using 5, 10, 15, 20-Tetrakis (Carboxyphenol) Porphine’.

Biomoda CEO Maria Zannes said their patent portfolio is the foundation of their strategy to impact the five-year survival rate for lung cancer by giving doctors to access to a non-invasive diagnostic.

In March 2011 Biomoda completed the pilot clinical trial of the CyPath assay and plans to seek the US Food and Drug Administration approval for its cytology-based diagnostic technology as a medical device.

Biomoda plans to develop assays for cervical, breast, colorectal, bladder, and oral cancers.